Biomarkers /
MYCL
Overview
V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog (MYCL) is a gene that encodes a protein that functions in DNA binding. Missense mutations, nonsense mutations, silent mutations, and frameshift insertions are observed in cancers such as liver cancer, lung cancer, and skin cancer.
MYCL is altered in 0.98% of all cancers with lung adenocarcinoma, bladder urothelial carcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MYCL are MYCL Mutation (0.58%), MYCL Amplification (0.40%), MYCL Loss (0.05%), MYCL S299L (0.03%), and MYCL T132I (0.05%) [3].
Clinical Trials
Significance of MYCL in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.